PEN(Penumbra, Inc.) 的财务报表:医疗保健,医疗器械。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $747.59M | $847.13M | $1.06B | $1.19B | $1.40B |
| 毛利润 | $475.38M | $535.21M | $682.64M | $755.00M | $942.44M |
| 营业利润 | −$7.50M | $6.08M | $73.55M | $9.28M | $189.25M |
| 净利润 | $5.28M | −$2.00M | $90.95M | $14.01M | $177.69M |
| 经营现金流 | $9.50M | −$55.66M | $97.33M | $168.48M | $238.66M |
| 自由现金流 | −$11.68M | −$74.96M | $82.12M | $147.30M | $174.93M |
| 摊薄每股收益 | $0.14 | $-0.05 | $2.32 | $0.36 | $4.52 |